Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

Rhea-AI Summary

Nuvation Bio (NYSE: NUVB) announced that taletrectinib (IBTROZI) was added to the NCCN Clinical Practice Guidelines for Central Nervous System (CNS) cancers on April 24, 2026, as a systemic therapy option for ROS1-positive NSCLC patients with brain metastases. The drug previously was listed as a Preferred Agent in NCCN NSCLC guidelines and is FDA-approved for locally advanced or metastatic ROS1+ NSCLC. Clinical data cited include intracranial overall response rates of 76.5% in TKI-naive patients and 65.6% in TKI-pretreated patients, presented at AACR April 2026.

Positive

• Added to NCCN CNS guidelines as a systemic option for ROS1+ NSCLC with brain metastases
• Previously listed as NCCN Preferred Agent for first-line and subsequent therapy in NSCLC
• FDA approval in place for locally advanced or metastatic ROS1+ NSCLC
• Intracranial ORR of 76.5% in TKI-naive patients (AACR April 2026)
• Intracranial ORR of 65.6% in TKI-pretreated patients (AACR April 2026)

Negative

• Target population is small: ROS1+ NSCLC represents ~2% of new NSCLC cases, limiting addressable patient pool

News Market Reaction – NUVB

-6.75% 1.8x vol

14 alerts

-6.75% Session close to close

-10.9% Trough in 6 hr 14 min

$1.79B Market Cap

1.8x Rel. Volume

In the Apr 27 session, NUVB declined 6.75%, reflecting a notable negative market reaction. Argus tracked a trough of -10.9% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.8% in the session following this news. A negative reaction despite guideline reco...

Analysis

The stock moved -6.8% in the session following this news. A negative reaction despite guideline recognition fits a pattern where prior positive milestones, such as EMA validation on Mar 26 and robust TRUST data on Apr 21, were followed by declines of 3.85% and 0.49%. The move could have been amplified by already elevated volume of 4.2M shares and recent insider selling activity, and may have led some market participants to reassess how much of taletrectinib’s CNS potential was already reflected in the stock.

Key Figures

Intracranial ORR (TKI-naïve): 76.5% Intracranial ORR (TKI-pretreated): 65.6% ROS1+ NSCLC share: 2% +2 more

5 metrics

Intracranial ORR (TKI-naïve) 76.5% ROS1+ NSCLC patients with brain metastases

Intracranial ORR (TKI-pretreated) 65.6% ROS1+ NSCLC patients with brain metastases

ROS1+ NSCLC share 2% Share of new NSCLC cases

Median age at diagnosis 50 years Patients with ROS1+ NSCLC

NCCN member centers 33 centers Alliance of leading cancer centers

Historical Context

5 past events · Latest: Apr 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 21	Clinical data update	Positive	-0.5%	Pooled TRUST data showed durable responses and manageable safety for IBTROZI.
Apr 21	Clinical data update	Positive	-0.5%	Update emphasizing strong intracranial responses and survival metrics for taletrectinib.
Apr 20	Earnings timing	Neutral	-0.2%	Announcement of date and logistics for Q1 2026 earnings and business update.
Apr 01	Asset acquisition	Positive	+5.1%	Acquisition of Japan rights to safusidenib, expanding Phase 3 SIGMA study footprint.
Mar 26	Regulatory milestone	Positive	-3.9%	EMA validation of taletrectinib MAA for advanced ROS1-positive NSCLC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent taletrectinib and regulatory milestones often saw negative or muted next-day moves, while the safusidenib rights acquisition drew a stronger positive reaction.

Recent Company History

Over the past month, Nuvation Bio has reported several milestones tied to taletrectinib and its broader pipeline. On Mar 26, EMA validation of the taletrectinib MAA saw shares fall 3.85%. An acquisition of Japan rights to safusidenib on Apr 1 drew a 5.13% gain. Long-term TRUST-I/II taletrectinib data presented on Apr 21 coincided with a modest 0.49% decline. Today’s NCCN CNS guideline inclusion extends this sequence of positive, CNS-focused developments around taletrectinib.

Key Terms

central nervous system, brain metastases, non-small cell lung cancer, ros1-positive, +4 more

8 terms

central nervous system medical

"Guidelines in Oncology for Central Nervous System (CNS) cancers"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

brain metastases medical

"NSCLC patients with brain metastases."

Cancer cells that have spread from another part of the body to the brain, forming new tumors there. Think of it like weeds from one garden taking root in another; the behavior and treatment needs can change significantly once cancer reaches the brain. For investors, brain metastases matter because they often drive different clinical trial designs, higher healthcare costs, and urgent demand for effective therapies, all of which can materially affect a biotech or healthcare company’s prospects.

non-small cell lung cancer medical

"ROS1-positive non-small cell lung cancer (NSCLC) patients"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

ros1-positive medical

"systemic therapy option for ROS1-positive (ROS1+) non-small cell lung cancer"

ROS1-positive describes a tumor that carries a specific genetic change in the ROS1 gene, meaning the cancer cells use an abnormal instruction that can drive their growth. For investors, this matters because ROS1-positive status identifies patients who may respond to targeted drugs designed like a key fitting a particular lock, shaping the potential market size, trial outcomes, regulatory approvals, and revenue prospects for therapies aimed at that patient group.

tyrosine kinase inhibitor medical

"a highly selective, next-generation ROS1 tyrosine kinase inhibitor (TKI)"

A tyrosine kinase inhibitor is a type of drug that blocks specific proteins in cells that act like on/off switches for growth and survival signals, often used to stop cancer cells from multiplying. For investors, these drugs matter because their clinical trial results, regulatory approvals, safety profiles, and patent status drive sales potential and company valuation—think of them as precision tools whose effectiveness and market exclusivity determine commercial success.

intracranial overall response rate medical

"a 76.5% intracranial overall response rate in TKI-naive patients"

Intracranial overall response rate measures the share of patients in a clinical trial whose brain tumors shrink or disappear after treatment. Think of it as the percentage of potholes on a road that get fixed — it gives a quick snapshot of whether a therapy is having a visible effect inside the skull. Investors watch it because higher rates can indicate a drug’s effectiveness against brain disease, influencing regulatory decisions, market potential and commercial value.

nccn guidelines regulatory

"added to the latest National Comprehensive Cancer Network Clinical Practice Guidelines"

NCCN Guidelines are evidence-based recommendations for cancer diagnosis, treatment and care developed by a network of cancer specialists; think of them as an expert-approved roadmap clinicians use to choose therapies. They matter to investors because inclusion or alignment with these guidelines can speed clinical adoption, influence insurance coverage and reimbursement, and signal clinical credibility — all of which affect a treatment’s commercial potential and a company’s market value.

rule 10b5-1 trading plan financial

"sales were made under a pre-arranged Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases

NEW YORK, April 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI^®) has been added to the latest National Comprehensive Cancer Network^® Clinical Practice Guidelines (NCCN Guidelines^®) in Oncology for Central Nervous System (CNS) cancers, updated on April 24, 2026. Specifically, the NCCN Guidelines^® for CNS Cancers now recommend taletrectinib (IBTROZI) as a systemic therapy option for ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) patients with brain metastases.

The NCCN previously added taletrectinib (IBTROZI) as a Preferred Agent for both first-line and subsequent therapy for ROS1+ NSCLC in its Clinical Practice Guidelines in Oncology for NSCLC in June 2025, after its approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Taletrectinib (IBTROZI) is a highly selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to address some of the outstanding challenges of treating the disease. Taletrectinib (IBTROZI) has demonstrated efficacy in patients with brain metastases with a 76.5% intracranial overall response rate in TKI-naive patients and a 65.6% intracranial response rate among TKI-pretreated patients, as recently presented at the American Association of Cancer Research (AACR) Annual Meeting in April 2026.

"We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines^® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "Given the prevalence of CNS tumors among ROS1+ NSCLC patients, taletrectinib (IBTROZI) can address a critical need for these patients, offering meaningful brain penetrance while maintaining a favorable neurologic safety profile. Additionally, with this update, taletrectinib (IBTROZI) is now one of the few therapies to be added by NCCN to both NSCLC and CNS guidelines."

ROS1+ NSCLC is a rare and aggressive form of lung cancer, accounting for approximately 2% of new NSCLC cases. The median age at diagnosis for patients with this type of lung cancer is approximately 50 years old, and the disease is more likely to occur in people who have never smoked. Brain metastases are common and a leading cause of disease progression and mortality in this population.

The NCCN is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

The updated NCCN Guidelines are available at www.nccn.org.

About ROS1+ NSCLC
Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain. The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.

About IBTROZI
IBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved IBTROZI for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more at IBTROZI.com. 

About the TRUST Clinical Program
 The TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of IBTROZI. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating IBTROZI for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating IBTROZI for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating IBTROZI versus crizotinib in 194 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs. 

Indication
IBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC).

IMPORTANT SAFETY INFORMATION FOR IBTROZI^®(taletrectinib) 

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).

Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.

Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.

Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).

ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.

QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.

In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.

Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.

Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.

Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).

Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.

Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.

Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.

ADVERSE REACTIONS
Among patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).

The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).

DRUG INTERACTIONS

• Strong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.
• Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI.

OTHER CONSIDERATIONS

• Pregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity.
• Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.
• Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.
• Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.
• Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation.

Please see accompanying full Prescribing Information.

About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI^®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. 

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc). 

Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements about the needs of ROS1+ NSCLC patients with brain metastases and IBTROZI's therapeutic potential for such patients. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to whether Nuvation Bio is successful in commercializing IBTROZI; the challenges associated with conducting drug discovery and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; whether Nuvation Bio meets its post-marketing requirements and commitments for IBTROZI; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-K filed with the SEC on March 2, 2026 under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Media and Investor Contacts

Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com

Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-announces-national-comprehensive-cancer-network-adds-taletrectinib-ibtrozi-as-recommended-option-to-clinical-practice-guidelines-in-oncology-for-central-nervous-system-cancers-302753406.html

SOURCE Nuvation Bio Inc.

FAQ

What did NUVB announce about taletrectinib (IBTROZI) on April 24, 2026?

NUVB announced taletrectinib was added to the NCCN CNS Guidelines as a systemic option for ROS1+ NSCLC with brain metastases. According to Nuvation Bio, this follows its prior NCCN Preferred Agent listing and FDA approval.

How effective is taletrectinib (IBTROZI) in treating brain metastases in ROS1+ NSCLC patients?

Taletrectinib showed high intracranial response rates: 76.5% in TKI-naive and 65.6% in TKI-pretreated patients. According to Nuvation Bio, these figures were presented at AACR in April 2026.

Does NCCN now recommend taletrectinib for NSCLC and CNS guidelines for ROS1+ disease?

Yes. NCCN added taletrectinib to CNS guidelines and previously listed it as a Preferred Agent for ROS1+ NSCLC. According to Nuvation Bio, it is now included in both NSCLC and CNS NCCN guidance.

Is taletrectinib (IBTROZI) FDA-approved for ROS1+ NSCLC?

Yes. Taletrectinib is FDA-approved for adult patients with locally advanced or metastatic ROS1+ NSCLC. According to Nuvation Bio, the NCCN updates build on that approval and prior guideline placement.

What patient group is primarily affected by the NCCN inclusion of taletrectinib (IBTROZI)?

The inclusion targets ROS1-positive NSCLC patients who have brain metastases, a subgroup with significant CNS involvement. According to Nuvation Bio, ROS1+ disease accounts for about 2% of new NSCLC cases.

Where can clinicians find the updated NCCN Guidelines for CNS cancers including taletrectinib?

Clinicians can access the updated NCCN CNS Guidelines on the NCCN website. According to Nuvation Bio, the guidelines were updated April 24, 2026 and list taletrectinib as a systemic option.